qxp 03 07 2018 12:26 Page 28 Governance Report of the Directors The Directors present their Annual Report on the affairs of In order to ensure that only sustained outperformance is the Company together with the audited financial statements rewarded, at each quarterly calculation date any performance and the Independent Auditors Report for the year ended fee payable is based on the lower of: 31 March 2018. i The cumulative outperformance of the portfolio over the Benchmark as at the quarter end date: and Significant agreements ii The cumulative outperformance of the portfolio over the Details of the services provided under these agreements are Benchmark as at the corresponding quarter end date in the included in the Strategic Report on pages 21 to 22. previous year.
Alternative Investment Fund Management The effect of this is that outperformance has to be maintained agreement for a twelve month period before it is paid.
As described on page 21, Frostrow is the designated AIFM for In addition, a performance fee only becomes payable to the the Company on the terms and subject to the conditions of the extent that the cumulative outperformance gives rise to a total alternative investment fund management agreement between fee greater than the total of all performance fees paid to date.
the Company and Frostrow the AIFM Agreement.
The performance fee charge for the year was 9.7m and is The notice period on the AIFM Agreement with Frostrow is represented by a provision for potential future performance 12 months, termination can be initiated by either party.
fee payments of 9.7m as at 31 March 2018.
The 2017 charge of 4.7m comprised of a 3.4m provision for potential future During the year under review, Frostrow charged a variable performance fees as at 31 March 2017 and 1.3m of base fee, which was dependent on the size of the Company.
performance fees that crystallised and became payable Further details of this fee can be found on page 21. during the year ended 31 March 2017.
Portfolio management agreement The maximum amount that could become payable by 31 March Under the AIFM Agreement Frostrow has delegated the 2019 is 9.7m if the current level of outperformance is portfolio management function to OrbiMed, under a portfolio maintained.
The 3.4m provided for as at 31 March 2017 management agreement between it, the Company and crystallised during the year.
2.4m has been paid in Frostrow the Portfolio Management Agreement.
accordance with the performance fee provisions and 1.0m is payable as at 31 March 2018.
OrbiMed receives a periodic fee equal to 0.65% p. a. of the Companys NAV and a performance fee as set out in the Depositary agreement Performance Fee section below.
Its agreement with the The Company appointed J. P. Morgan Europe Limited the Company may be terminated by either party giving notice of Depositary as its Depositary in accordance with the not less than 12 months.
AIFMD on the terms and subject to the conditions of the Depositary agreement between the Company, Frostrow and Performance fee the Depositary the Depositary Agreement.
Dependent on the level of long-term outperformance of the Company, OrbiMed is entitled to a performance fee.
The Under the terms of the Depositary Agreement the Company performance fee is calculated by reference to the amount by has agreed to pay the Depositary a fee calculated at 1.75bp which the Companys NAV performance has outperformed on net assets up to 150 million, 1.50 bps on net assets the Benchmark see inside front cover for details of the between 150 million and 300 million, 1.00bps on net Benchmark.
assets between 300 million and 500 million and 0.50bps on net assets above 500 million.
The fee is calculated quarterly by comparing the cumulative performance of the Companys NAV with the cumulative The Depositary has delegated the custody and safekeeping of performance of the Benchmark since the launch of the the Companys assets to J. P. Morgan Securities LLC the Company in 1995.
The performance fee amounts to 15.0% of any Custodian and Prime Broker pursuant to a delegation outperformance over the Benchmark.
Provision is made within agreement between the Company, Frostrow, the Depositary and the daily NAV per share calculation as required and in the Custodian and Prime Broker the Delegation Agreement.
accordance with generally accepted accounting standards.
Worldwide Healthcare Trust PLC 28 Annual Report for the year ended 31 March 2018 249336 WWH pp26-pp31.
qxp 03 07 2018 12:26 Page 29 Governance Report of the Directors The Delegation Agreement transfers the Depositarys liability Continuation of the Company for the loss of the Companys financial instruments held in In accordance with the Companys Articles of Association, custody by the Custodian and Prime Broker to the Custodian shareholders will have an opportunity to vote on the and Prime Broker in accordance with the AIFMD.
The continuation of the Company at the 2019 Annual General Company has consented to the transfer and reuse of its Meeting and every five years thereafter.
assets by the Custodian and Prime Broker known as The rules concerning the amendment of the Companys rehypothecation in accordance with the terms of an Articles of Association are contained in the Companys institutional account agreement between the Company, the Articles of Association and in the Companies Act 2006.
Custodian and Prime Broker and certain other J. P. Morgan entities as defined therein.
See page 23 for further details.
Results and dividends The results attributable to shareholders for the year and the Prime brokerage agreement transfer to reserves are shown on pages 52 to 54.
Details of The Company appointed J. P. Morgan Securities LLC on the the Companys dividend record can be found on page 3. terms and subject to the conditions of the prime brokerage agreement between the Company, Frostrow and the Beneficial owners of shares information Depositary the Prime Brokerage Agreement.
The rights Custodian and Prime Broker receives interest on the drawn Beneficial owners of shares who have been nominated by overdraft as detailed in note 12 on page 63. the registered holder of those shares to receive information The Custodian and Prime Broker is a registered broker-dealer rights under section 146 of the Companies Act 2006 are and is regulated by the United States Securities and Exchange required to direct all communications to the registered Commission.
holder of their shares rather than to the Companys registrar, Link Asset Services, or to the Company directly.
Directors & officers liability insurance cover Directors & officers liability insurance cover was maintained by the Company during the year ended 31 March 2018.
It is intended that this policy will continue for the year ending 31 March 2019 and subsequent years.
Substantial interests in share capital The Company was aware of the following substantial interests in the voting rights of the Company as at 31 May 2018, the latest practicable date before publication of the Annual Report: 31 May 2018 31 March 2018 Number of % of issued Number of % of issued Shareholder shares share capital shares share capital Investec Wealth & Investment Limited 6,074,115 12.2 6,080,733 12.2 Alliance Trust Savings Limited 3,105,309 6.2 3,044,751 6.1 Rathbone Brothers plc 2,969,141 5.9 2,959,766 5.9 Hargreaves Lansdown plc 2,428,970 4.9 2,435,123 4.9 Charles Stanley & Co Limited 2,359,221 4.7 2,267,585 4.6 Speirs & Jeffrey Limited 2,149,338 4.3 2,136,223 4.3 Quilter Cheviot Investment Management 2,033,143 4.1 2,076,343 4.2 As at 31 March 2018 the Company had 49,861,278 shares in issue.
As at 31 May 2018 there were 49,968,778 shares in issue.
Worldwide Healthcare Trust PLC Annual Report for the year ended 31 March 2018 29 249336 WWH pp26-pp31.
qxp 03 07 2018 12:26 Page 30 Governance Report of the Directors behalf of the Company, from accepting, soliciting, paying, Directors indemnities offering or promising to pay or authorise any payment, During the year under review and to the date of this report, public or private in the UK or abroad to secure any improper indemnities were in force between the Company and each of its benefit for themselves or for the Company.
Directors under which the Company has agreed to indemnify The Board ensures that its service providers apply the same each Director, to the extent permitted by law, in respect of certain liabilities incurred as a result of carrying out his or her standards in their activities for the Company.
role as a Director of the Company.
The Directors are also A copy of the Companys Anti Bribery and Corruption Policy indemnified against the costs of defending any criminal or civil can be found on its website at www.
The proceedings or any claim by the Company or a regulator as they policy is reviewed regularly by the Audit Committee.
are incurred provided that where the defence is unsuccessful the Director must repay those defence costs to the Company.
Criminal Finances Act 2017 The indemnities are qualifying third party indemnity provisions The Company has a commitment to zero tolerance towards for the purposes of the Companies Act 2006. the criminal facilitation of tax evasion.
A copy of each deed of indemnity is available for inspection Global greenhouse gas emissions at the Companys registered office during normal business The Company has no greenhouse gas emissions to report hours and will be available for inspection at the Annual from its operations, nor does it have responsibility for any General Meeting.
other emissions producing sources under Large and Medium sized Companies and Groups Accounts and Capital structure Reports Regulations 2008 as amended, including those The Companys capital structure is composed solely of ordinary within our underlying investment portfolio.
During the year under review and to the date of this report, no Common Reporting Standard CRS shares were bought back by the Company to be held in CRS is a global standard for the automatic exchange of treasury.
information commissioned by the Organisation for Economic During the year, a total of 3,355,000 new shares were issued Cooperation and Development and incorporated into UK law at an average premium of 0.7% to the prevailing cum income by the International Tax Compliance Regulations 2015.
requires the Company to provide certain additional details to Since the year end, to the date of this report, 107,500 new HMRC in relation to certain shareholders.
The reporting shares have been issued at an average premium of 0.7% to the obligation began in 2016 and will be an annual requirement prevailing cum income NAV per share.
The Registrars, Link Asset Services, have been engaged to collate such information and file the Voting rights in the Companys shares reports with HMRC on behalf of the Company.
Details of the voting rights in the Companys shares at the date of this Annual Report are given in note 9 to the Notice of Corporate governance Annual General Meeting on page 80.
The Corporate Governance Statement is set out on pages 32 to 39.
Political and charitable donations The Company has not in the past and does not intend in the Requirements of the Listing Rules future to make political or charitable donations.
4 requires the Company to include certain information in a single identifiable section of the Annual Modern Slavery Act 2015 Report or a cross reference table indicating where the The Company does not provide goods or services in the information is set out.
The Directors confirm that there are normal course of business, and as a financial investment no disclosures to be made under Listing Rule 9.8.
4. vehicle does not have customers.
The Directors do not therefore consider that the Company is required to make a statement under the Modern Slavery Act 2015 in relation to By order of the Board slavery or human trafficking.
Anti-bribery and corruption policy Frostrow Capital LLP The Board has adopted a zero tolerance approach to Company Secretary instances of bribery and corruption.
Accordingly it expressly prohibits any Director or associated persons when acting on 15 June 2018 Worldwide Healthcare Trust PLC 30 Annual Report for the year ended 31 March 2018
